A total of approximately 50 healthy male and female subjects will be enrolled into about seven cohorts (6 or 8 subjects per cohort). Subjects who meet eligibility criteria at screening will be admitted for baseline evaluations (Day -1). All baseline safety evaluation results must be available prior to dosing. The doses will be progressively escalated, with a sentinel dosing strategy employed for all seven cohorts.
This will be a single center, randomized, double-blind, placebo-controlled, single ascending dose study in healthy adult subjects.